Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalpeer-review

2 Scopus Citations
View graph of relations

Author(s)

  • Gary Tse
  • Sharen Lee
  • Wing Tak Wong
  • Xintao Li
  • Tong Liu
  • Zhidong Cao
  • Daniel Dajun Zeng
  • Abraham K.C. Wai
  • Ian Chi Kei Wong
  • Bernard Man Yung Cheung

Related Research Unit(s)

Detail(s)

Original languageEnglish
Pages (from-to)1717-1724
Journal / PublicationJournal of Hypertension
Volume39
Issue number8
Online published9 Apr 2021
Publication statusPublished - Aug 2021

Abstract

Background: Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may be associated with higher susceptibility of COVID-19 infection and adverse outcomes. We compared ACEI/ARB use and COVID-19 positivity in a case–control design, and severity in COVID-19 positive patients.

Methods: Consecutive patients who attended Hong Kong's public hospitals or outpatient clinics between 1 January and 28 July 2020 for COVID-19 real time-PCR (RT-PCR) tests were included. Baseline demographics, past comorbidities, laboratory tests and use of different medications were compared between COVID-19 positive and negative patients. Severe endpoints for COVID-19 positive patients were 28-day mortality, need for intensive care admission or intubation.

Results: This study included 213 788 patients (COVID-19 positive: n = 2774 patients; negative: n = 211 014). In total, 162 COVID-19 positive patients (5.83%) met the severity outcome. The use of ACEI/ARB was significantly higher amongst cases than controls (n = 156/2774, 5.62 vs. n = 6708/211014, 3.17%; P < 0.0001). Significant univariate predictors of COVID-19 positivity and severe COVID-19 disease were older age, higher Charlson score, comorbidities, use of ACEI/ARB, antidiabetic, lipid-lowering, anticoagulant and antiplatelet drugs and laboratory tests (odds ratio >1, P < 0.05). The relationship between the use of ACEI/ARB and COVID-19 positivity or severe disease remained significant after multivariable adjustment. No significant differences in COVID-19 positivity or disease severity between ACEI and ARB use were observed (P > 0.05).

Conclusion: There was a significant relationship between ACEI/ARB use and COVID-19 positivity and severe disease after adjusting for significant confounders.

Research Area(s)

  • angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, COVID-19 incidence

Citation Format(s)

Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease. / Tse, Gary; Zhou, Jiandong; Lee, Sharen; Wong, Wing Tak; Li, Xintao; Liu, Tong ; Cao, Zhidong; Zeng, Daniel Dajun; Wai, Abraham K.C.; Wong, Ian Chi Kei; Cheung, Bernard Man Yung; Zhang, Qingpeng.

In: Journal of Hypertension, Vol. 39, No. 8, 08.2021, p. 1717-1724.

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalpeer-review